Changes in 5-HT_2A Receptor Expression in Untreated, de novo Patients with Parkinson's Disease

Issue title: Mental Dysfunction in Parkinson's Disease

Article type: Research Article

Authors: Melse, Maartje^; | Tan, Sonny K.H.^; | Temel, Yasin^; | van Kroonenburgh, Marinus J.P.G. | Leentjens, Albert F.G.^;

Affiliations: Department of Neuroscience, Maastricht University, Maastricht, The Netherlands | Department of Neurosurgery, Maastricht University Medical Center, Maastricht, The Netherlands | Department of Neurosurgery, University Hospital RWTH Aachen, Aachen, Germany | Department of Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands | Department of Psychiatry, Maastricht University Medical Center, Maastricht, The Netherlands

Note: [] Correspondence to: A.F.G. Leentjens, Tel.: +31 43 3877443; Fax: +31 43 3875444; E-mail: a.leentjens@maastrichtuniversity.nl

Abstract: Background: Serotonin (5-HT) has long been implied in the pathophysiology of Parkinson's disease (PD). In addition, the 5-HT2A receptor is associated with the regulation of motor function and mood. Objective: To assess regional 5-HT2A receptor expression in unmedicated patients with de novo PD. Methods: Eight de novo, drug naïve patients with PD and eight healthy control subjects underwent a single photon emission computed tomography (SPECT) scan with the highly selective 5-HT2A radioligand 123I-5-I-R91150. Results: In de novo PD patients 5-HT2A receptor binding was significantly reduced in the anterior striatum and the premotor cortex in PD patients compared to controls. In addition, occipital binding was elevated in PD patients. No changes in 5-HT2A receptor binding were found in the prefrontal and parietal cortex. Conclusion: In de novo PD patients, 5-HT2A receptor expression is changed in key areas of the basal ganglia-thalamocortical motor circuit and occipital cortex. This suggests altered 5-HT neurotransmission to contribute to development of PD motor and non-motor symptoms.

Keywords: 5-HT$_{2A}$ receptor, serotonin, Parkinson's disease, neuroimaging

DOI: 10.3233/JPD-130300

Journal: Journal of Parkinson's Disease, vol. 4, no. 2, pp. 283-287, 2014